Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
841 to 860 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| R01HL138749 | The roles of miR-155 in regulating atherosclerosis and metabolically healthy obesity | 3 | 2020 |
| R03CA219764 | Mechanistic Insight on the Role of Berberine and AMPK in Hepatocellular Carcinoma | 3 | 2020 |
| R37AI095983 | Genome-Wide Dissection of Mendelian Susceptibility to Mycobacterial Disease | 3 | 2020 |
| T32CA009035 | Training Program in Cancer Research | 3 | 2020 |
| K23GM120630 | Epigenetic mediated long-term aberrations in myeloid cells after critical illness | 2 | 2020 |
| K24CA208132 | Mentored Patient Oriented Research in Lymphoma | 2 | 2020 |
| R01AI122176 | Endocytic Control of Autophagosome Formation in Lupus T cells | 2 | 2020 |
| R01AR071522 | Fine mapping rheumatic disease variants using functional genomic sequencing | 2 | 2020 |
| R01CA201189 | NK cell exhaustion in metastatic melanoma | 2 | 2020 |
| R01CA204552 | MUC13 Mucin in Colerectal Cancer Health Disparity | 2 | 2020 |
| R21CA231252 | Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells | 2 | 2020 |
| T32GM088088 | Molecular Medicine Training Program | 2 | 2020 |
| F30CA206255 | The role of paracrine WNT5A/RYK in ErbB2-driven tumorigenesis | 1 | 2020 |
| F30CA216966 | Microenvironmental FGF2-mediated resistance to anti-estrogen and PI3K/mTOR pathway therapeutics in ER+ breast cancer | 1 | 2020 |
| F31DE027854 | Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancers | 1 | 2020 |
| F31HL143905 | Role of Tuberin S1365 Phosphorylation in mTORC1 Regulation | 1 | 2020 |
| K08AR069111 | Defining T helper cell associated cytokines and mechanisms in Alopecia Areata | 1 | 2020 |
| K08CA201483 | Investigating L-2-hydroxyglutarate in normal hematopoiesis and leukemogenesis | 1 | 2020 |
| K08CA208013 | Oncogenic programs driven by notch signaling in B-cell lymphoma | 1 | 2020 |
| P01HL048546 | Pathophysiology and Treatment of Fanconi Anemia | 1 | 2020 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=43